HemaSphere

Age‐ and gender‐specific molecular characteristics of diffuse large B‐cell lymphoma: Results from clinical trials of the DSHNHL/GLA

Nature Cancer

Odronextamab monotherapy in patients with relapsed/refractory diffuse large B cell lymphoma: primary efficacy and safety analysis in phase 2 ELM-2 trial

2025 Transplantation & Cellular Therapy Meetings Abstract

Tandem CD20-CD19-directed non-cryopreserved CAR T cells - zamtocabtagene autoleucel (Zamto-Cel) in patients with relapsed/refractory diffuse large B cell lymphoma - interim results from a phase 2 pivotal study (DALY II USA)

The Lancet

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial

OncLive

ctDNA testing joins NCCN Guidelines for MRD assessment in DLBCL

Journal of Clinical Oncology

Brentuximab vedotin combination for relapsed diffuse large B-cell lymphoma

2024 American Society of Hematology Annual Meeting Abstract

Five-year analysis of the POLARIX study: Prolonged follow-up confirms positive impact of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) on outcomes

2024 American Society of Hematology Annual Meeting Abstract

Real-world effectiveness of tafasitamab (Tafa) for the treatment of relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) in the United States

2024 American Society of Hematology Annual Meeting Abstract

Time of CAR-T failure is a strong predictor of outcome for bispecific antibody therapy in relapsed/refractory large B-cell lymphoma

2024 American Society of Hematology Annual Meeting Abstract

Open-label phase 2 study results of FS118, a LAG-3/PD-L1 bispecific antibody, in patients with relapsed/refractory diffuse large B-cell lymphoma